mediacenter.23andme.comPress Release - 23andMe Media Center

Press Releases Investors Speaker Request go to 23andMe.com 2024 Feb 7, 2024 23andMe Reports Third Quarter Fiscal 2024 Financial Results Jan 31, 2024 23andMe Announces FDA Clearance of IND Application for its Dual Mechanism Antibody, 23ME-01473, Targeting ULBP6 Jan 30, 2024 23andMe Launches Month-Long Initiative to Amplify ARRAY’s Seat16” Program for Acclaimed Film ORIGIN by Ava DuVernay Jan 24, 2024 23andMe to Report FY2024 Third Quarter Financial Results 2023 Dec 19, 2023 23andMe announces further expansion of 23ME-00610 Phase 1/2a clinical trial in advanced neuroendocrine and ovarian cancer patient cohorts Nov 8, 2023 23andMe Reports Second Quarter Fiscal 2024 Financial Results Nov 7, 2023 23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership Nov 6, 2023 23andMe Announces Updated Safety and Preliminary Efficacy Data From the Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 Oct 31, 2023 23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data Oct 30, 2023 23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK Oct 25, 2023 23andMe to Report FY2024 Second Quarter Financial Results Sep 27, 2023 23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting Sep 14, 2023 23andMe and Sickle Cell 101 Collaborate to Expand Sickle Cell Awareness Program Aug 31, 2023 23andMe Granted New FDA Clearance to Report Additional BRCA Variants Aug 8, 2023 23andMe Reports FY2024 First Quarter Financial Results Jul 25, 2023 23andMe to Report FY2024 First Quarter Financial Results Jul 20, 2023 23andMe Releases New FDA-Cleared Genetic Report on Simvastatin, a Commonly Prescribed Statin Jun 21, 2023 23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks May 25, 2023 23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results May 16, 2023 New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture May 11, 2023 23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results May 9, 2023 23andMe Releases New Report Revealing Likelihood of Developing Lupus May 8, 2023 Reza Afkhami Joins 23andMe as Chief Corporate Development Officer Apr 14, 2023 23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 Apr 11, 2023 Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program Mar 29, 2023 23andMe Publishes Inaugural Environmental, Social and Governance Report Mar 24, 2023 23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease Mar 14, 2023 23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023 Mar 9, 2023 New 23andMe Surveys Find Most People and Doctors Agree that Genetic Testing Offers Promise for More Personalized Healthcare Feb 28, 2023 23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies Feb 22, 2023 23andMe to Present at Upcoming Investor Conferences Feb 8, 2023 23andMe Reports FY2023 Third Quarter Financial Results Jan 26, 2023 23andMe to Report FY2023 Third Quarter Financial Results 2022 Dec 1, 2022 23andMe Survey Shows Majority of People Less Stressed About Their Health During This Holiday Season Nov 7, 2022 23andMe Reports FY2023 Second Quarter Financial Results Nov 7, 2022 23andMe Trials-in-Progress Poster Details Expansion Cohorts for 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting Oct 27, 2022 23andMe Granted New FDA Clearance to Provide Interpretive Drug Information for a Commonly Prescribed Cholesterol Medication Oct 24, 2022 23andMe to Report FY2023 Second Quarter Financial Results Oct 12, 2022 23andMe to Present at Upcoming Investor Conferences Oct 5, 2022 23andMe Announces Trials-in-Progress Poster Presentation on 23ME-00610, An Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2022 Annual Meeting Sep 19, 2022 Daniel Chu Joins 23andMe as Chief Product Officer Aug 8, 2022 23andMe Reports FY2023 First Quarter Financial Results Jul 25, 2022 23andMe to Report FY2023 First Quarter Financial Results May 26, 2022 23andMe Reports FY2022 Fourth Quarter and Full Year Financial Results May 12, 2022 23andMe to Report FY2022 Fourth Quarter and Full Year Financial Results Mar 15, 2022 23andMe to Present at American Association for Cancer Research (AACR) 2022 Annual Meeting Feb 25, 2022 23andMe to Present at Cowen 42nd Annual Health Care Conference Feb 17, 2022 23andMe to Present at Citi’s 2022 Virtual Healthcare Conference Feb 10, 2022 23andMe Reports FY2022 Third Quarter Financial Results Jan 27, 2022 23andMe to Report FY2022 Third Quarter Financial Results Jan 18, 2022 23andMe Announces Extension of GSK Collaboration and Update on Joint Immuno-oncology Program Jan 10, 2022 23andMe Receives FDA Clearance for Direct-to-Consumer Genetic Test on a Hereditary Prostate Cancer Marker Jan 6, 2022 23andMe Initiates Phase 1 Clinical Trial for First Wholly-Owned Immuno-oncology Antibody for Patients with Solid Tumors 2021 Dec 28, 2021 23andMe Announces the Results of the Completed Redemption of All Outstanding Warrants Nov 30, 2021 23andMe Announces the Appointment of Joseph R. Arron, M.D., Ph.D. as Chief Scientific Officer Nov 22, 2021 23andMe Announces Redemption of All Outstanding Warrants Nov 10, 2021 23andMe Reports FY2022 Second Quarter Financial Results Nov 9, 2021 23andMe to Present at Upcoming Virtual Healthcare Conferences Nov 9, 2021 23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors Nov 3, 2021 23andMe Provides Updated Timing for FY2022 Second Quarter Financial Results and Announces New Online Q&A Platform for Shareholders Nov 1, 2021 23andMe Announces the Closing of its Acquisition of Lemonaid Health Oct 22, 2021 23andMe Agrees to Acquire Lemonaid Health Oct 20, 2021 23andMe to Report FY2022 Second Quarter Financial Results on November 10, 2021 Sep 1, 2021 23andMe to Present at the Wells Fargo Healthcare Conference Aug 13, 2021 23andMe Reports FY2022 First Quarter Financial Results Jul 29, 2021 23andMe to Report FY2022 First Quarter Financial Results Jun 21, 2021 Industry Leaders Join 23andMe Board of Directors Jun 16, 2021 23andMe Successfully Closes its Business Combination with VG Acquisition Corp. Jun 2, 2021 D. Wade Walke, Ph.D. Joins 23andMe as Vice President of Investor Relations May 5, 2021 Virgin Group’s VG Acquisition Corp. Filed Amended Form S-4 in Connection with its Pending Business Combination with 23andMe Feb 4, 2021 23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics Feb 4, 2021 23andMe to Merge with Virgin Group’s VG Acquisition Corp. to Become Publicly-Traded Company Set to Revolutionize Personalized Healthcare and Therapeutic Development through Human Genetics January 15, 2021 Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health testing Jan 15, 2021 Medscape study in collaboration with 23andMe finds Primary Care Physicians are increasingly more comfortable with direct-to-consumer genetic health testing 2020 Nov 18, 2020 23andMe Finds Pandemic is Forcing Majority of People to Change Holiday Plans Aug 18, 2020...